Related Experiment Video
Updated: Jun 9, 2026
An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers
Published on: December 1, 2017
[Assessment of effectiveness of immunization against Hib-infection]
Insights
The Act-HIB vaccine effectively prevents acute respiratory diseases in children, reducing infection rates by 27% and complications by 50%. This immunization also lowers antibiotic use and healthcare visits.
Area of Science:
- Pediatric infectious diseases
- Vaccinology
- Public health
Context:
- Acute respiratory diseases (ARDs) pose a significant health burden in children aged 1-5 years.
- The Haemophilus influenzae type b (Hib) vaccine is a key intervention for preventing invasive Hib disease.
- Effectiveness of Hib vaccines against non-invasive ARDs requires further investigation.
Purpose:
- To evaluate the efficacy of the Act-HIB vaccine in preventing acute respiratory diseases in children.
- To assess the impact of Act-HIB immunization on the incidence, duration, and complications of ARDs.
- To determine the effect of Act-HIB vaccination on nasopharyngeal carriage of relevant pathogens.
Summary:
- A study involving 900 children aged 1-5 years compared outcomes between immunized and non-immunized groups.
- Clinical effectiveness was measured by ARD episode rates, disease duration, and complication development.
- Bacteriological tests assessed nasopharyngeal pathogen coverage post-immunization.
Impact:
- Act-HIB immunization demonstrated increased host resistance, reducing ARD incidence and altering complication patterns.
- Vaccination led to a 27% decrease in overall ARD incidence and a 50% reduction in pneumonia, bronchitis, and sinusitis.
- The study highlights reduced antibiotic consumption and fewer pediatric consultations following Act-HIB vaccination.
Aim:
To assess effectiveness of Act-HIB vaccine forprevention of acute respiratory diseases.
Materials And Methods:
Nine hundred immunized children 1 - 5 years old as well as not immunized children of the same age were followed-up. Criteria for clinical effectiveness of the vaccine were rate of acute respiratory infection episodes, duration of disease episode, and rate of complications development. Level of nasopharyngeal coverage were also studied by bacteriological tests of nasopharyngeal secretion samples.
Results:
Obtained data showed that immunization leads to increase of host's resistance capabilities, decrease of acute respiratory disease incidence and changes in structure of complications due to infection.
Conclusion:
Prevention of Hib-infection using Act-HIB vaccine leads to decrease of acute respiratory disease rates and severity of infections. Total incidence of acute respiratory infections in children aged 1 - 5 years decreased by 27%, whereas incidence of pneumonia, bronchitis, and sinusitis - by 50%. Vaccination resulted in decrease of antibiotic use, number of pediatric consultations.
Related Concept Videos
01:22Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
01:51Vaccinations